Compare Novo Nordisk A/S (NVO) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs DENTSPLY SIRONA Inc — how do they compare? Novo Nordisk A/S trades at $46.09 (market cap $207.85B), while DENTSPLY SIRONA Inc trades at $11.24 (market cap $2.31B). The key difference: Novo Nordisk A/S is far larger — about 90× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| NVO | XRAY | |
|---|---|---|
Market Cap | $207.85B | $2.31B |
Sector | Health | Health |
52-Week High | $63.98 | $14.68 |
52-Week Low | $35.29 | $9.64 |
Enterprise Value | $222.55B | $4.39B |
Dividend Yield | 3.81% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
DENTSPLY SIRONA (XRAY) trades at $11.66, down 3.8% on the day, with a bearish technical outlook and mixed fundamentals. The stock faces headwinds from declining revenue and negative profitability, though Q2 2026 earnings beat expectations. Recent news highlights institutional stake increases and ongoing turnaround efforts amid weak dental market conditions.
The outlook remains challenging with persistent net losses and high debt, but cost controls and strategic partnerships offer potential stabilization. Risks include competitive pressures and macroeconomic softness, while analyst consensus is Hold with a $11.50 price target, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
